Evidence map›Paper›PMID 41237125›Full record

ArticlePloS one2025

Disrupting ribulose-5-phosphate metabolic flux enhances riboflavin production in Escherichia coli BL21(DE3).

Junhui Ying, Jin Lu, Qiming Liu, Yingjie Pan, Xianfeng Bao, Junjun Yin, Bing Fu

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junhui YingCollege of Forestry Science and Technology, Lishui Vocational and Technical College, Lishui, Zhejiang, People's Republic of China.
Jin LuCollege of Medical Technology, Ningbo College of Health Sciences, Ningbo, Zhejiang, People's Republic of China.
Qiming LiuSongyang Rural Industry Development Center, Lishui, Zhejiang, People's Republic of China.
Yingjie PanSongyang Agricultural Products Quality and Safety Center, Lishui, Zhejiang, People's Republic of China.
Xianfeng BaoCollege of Forestry Science and Technology, Lishui Vocational and Technical College, Lishui, Zhejiang, People's Republic of China.
Junjun YinCollege of Forestry Science and Technology, Lishui Vocational and Technical College, Lishui, Zhejiang, People's Republic of China.
Bing FuCollege of Forestry Science and Technology, Lishui Vocational and Technical College, Lishui, Zhejiang, People's Republic of China.ORCID https://orcid.org/0000-0003-4831-7165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Riboflavin (vitamin B2) is an essential water-soluble vitamin. To increase its production in a previously engineered strain, R203, we employed metabolic engineering strategies to improve the supply of ribulose-5-phosphate, a key precursor. Disruption of the genes pfkA and edd-eda, which are aimed at promoting ribulose-5-phosphate generation, increased riboflavin production by 51.27% and 65.81%, respectively. To minimize the consumption of ribulose-5-phosphate, we disrupted kdsD and gutQ, both of which encode D-arabinose 5-phosphate isomerase. Only the disruption of gutQ was effective, increasing production by 19.65%, whereas kdsD disruption had no significant effect. Furthermore, disrupting yajO and inserting the pgl gene increased production by 8.65% and 18.80%, respectively. In contrast, inserting ribM, which encodes a riboflavin transporter from Streptomyces davawensis, reduced production. The final engineered strain, R19, achieved a riboflavin titer of 2,546.35 ± 159.65 mg/L, representing a 287.35% increase over that of the starting strain. This study provides an effective strategy for high-level riboflavin production in recombinant Escherichia coli BL21(DE3) strains.

Indexed as

Escherichia coliRiboflavinRibulosephosphatesEscherichia coli ProteinsMetabolic EngineeringEscherichia coli ProteinsRiboflavinribulose 5-phosphateRibulosephosphates

Identifiers

PMID41237125
PMCPMC12617950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.